Nifty 50
Tools & Calculators
Stocks
F&O
Mutual Funds
Sector: Pharmaceuticals & Biotechnology
|Large Cap
RUBICON
₹1,429
₹1385.00
₹1439.00
₹570.75
₹1468.70
Markets Today
Historical Performance
As of 10-07-2026 20:24, Rubicon Research Ltd. share price today is ₹0, with a change of ₹-1407.20 (-100.00%) from the previous close of ₹1407.2. The stock opened at ₹1411.1 and traded between ₹1385 and ₹1439, with a total traded volume of 189636 shares. The company has a market capitalization of ₹23272.7 Cr in the Pharmaceuticals & Biotechnology sector. while its 52-week high and low are ₹1468.7 and ₹570.75, respectively.
Rubicon Research Ltd. valuation metrics include a P/E ratio of 94.3, EPS of ₹15.52, and book value of ₹18.10. Profitability indicators show ROE of 19.14%. Rubicon Research Ltd. has reported revenue of ₹1753.96 Cr and net profit of ₹246.74 Cr.
Rubicon Research Ltd. technical indicators include Day RSI at 64.03, Day MFI at 68.3, Day ADX at 32.88. Additional indicators include Commodity Channel Index (CCI) at 91.2 and Williams %R at -33.72. Momentum indicators show Day MACD at 61.42, Day MACD Signal Line at 73.53, DayATR at 71.45. Rate of Change indicators for Rubicon Research Ltd. include ROC125 at 112.76 and ROC21 at 20.22.
Exponential moving averages include EMA5 at ₹1384.4, EMA10 at ₹1374.8, EMA12 at ₹1369.3, EMA20 at ₹1337.1, EMA26 at ₹1307.9, EMA50 at ₹1198.7, EMA100 at ₹1044.7. Simple moving averages include SMA5 at ₹1368.5, SMA10 at ₹1382.4, SMA20 at ₹1364.8, SMA30 at ₹1301.8, SMA50 at ₹1167.2, SMA100 at ₹986.1, SMA150 at ₹881.1.
Support levels for Rubicon Research are placed at First Support ₹1385.80, Second Support ₹1364.40, Third Support ₹1346.70. Resistance levels are seen at First Resistance ₹1424.90, Second Resistance ₹1442.60, Third Resistance ₹1464.00. Rubicon Research Ltd. shareholding pattern shows promoter holding at 59.86%, FII holding at 7.54%, DII holding at 0%, public holding at 22.57%.
Indicator | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 |
|---|---|---|---|---|---|
| Total Revenue | 389.88 | 301.71 | 336.47 | 278.03 | 300.81 |
| Operating Expense | 283.71 | 239.46 | 257.37 | 214.88 | 239.50 |
| Operating Profit | 106.17 | 62.25 | 79.10 | 63.14 | 61.30 |
| Depreciation | 10.17 | 9.51 | 9.78 | 8.30 | 8.57 |
| Interest | 5.40 | 7.51 | 9.21 | 8.85 | 10.78 |
| Tax | 24.16 | 12.35 | 15.82 | 12.28 | 13.66 |
| Net Profit | 70.02 | 37.18 | 45.81 | 35.15 | 40.27 |
₹1429.00
↗ Bullish Moving Average
14
↘ Bearish Moving Average
0
| Held By | Dec 2025 | Mar 2026 |
|---|---|---|
| Promoter | 60 | 59.9 |
| FII | 8 | 7.5 |
| DII | 9.4 | 10.1 |
| Public | 22.6 | 22.6 |
| Period | Combined Delivery Volume | NSE+BSE Traded Volume Avg | Daily Avg Delivery Volume % |
|---|---|---|---|
| Day | 1.11 L | 2.02 L | 55.09% |
| Week | 1.27 L | 2.76 L | 46.17% |
| 1 Month | 1.67 L | 4.78 L | 35.03% |
| 6 Month | 1.34 L | 4.06 L | 32.95% |
Benjamin Graham Value Screen
Companies with 10% increase in share price over three months, with rising net profit growth
Consistent high performing stocks over Five Years
Relative Outperformance versus Industry over 1 Month
Companies with high TTM EPS Growth
Expensive Performers (DVM)
Annual Profit Growth higher than Sector Profit Growth
PEG lower than Industry PEG
Stocks gaining versus previous close, open price and RSI
Relative Outperformance versus Industry over 1 Week
Relative Outperformance versus Industry over 1 Month
Efficient in managing Assets to generate Profits - ROA improving since last 2 year
Growth in Quarterly Net Profit with increasing Profit Margin (YoY)
Companies with Low Debt
Increasing profits every quarter for the past 4 quarters
Increasing Revenue every quarter for the past 3 quarters
Strong cash generating ability from core business - Improving Cash Flow from operation for last 2 years
Company able to generate Net Cash - Improving Net Cash Flow for last 2 years
Annual Net Profits improving for last 2 years
Book Value per share Improving for last 2 years
Companies with Zero Promoter Pledge
Near 52 Week High
Highest Recovery from 52 Week Low
RSI indicating price strength
Top Gainers
Stocks near 52 Week High with Significant Volumes
Stocks Outperforming their Industry Price Change in the Quarter
Ex-Date | Dividend Amount | Dividend Type | Record Date | Instrument Type |
|---|---|---|---|---|
| No Record Found | ||||
Financials | |||||
|---|---|---|---|---|---|
| Price (₹) | ₹754.95 | ₹1,265 | ₹1,805 | ₹2,523 | ₹176.50 |
| % Change | 0.39% | 2.48% | -0.25% | -0.36% | 2.62% |
| Revenue TTM (₹ Cr) | ₹2,124.33 | ₹2,192.49 | ₹9,203.54 | ₹14,277.64 | ₹8,869.07 |
| Net Profit TTM (₹ Cr) | ₹591.79 | ₹348.91 | ₹924.36 | ₹1,912.93 | ₹-325.93 |
| PE TTM | 71.60 | 75.10 | 37.10 | 54.70 | -70.30 |
| 1 Year Return | 31.93 | 57.98 | 43.82 | 0.21 | -14.62 |
| ROCE | 27.56 | 18.38 | 25.65 | 14.32 | 2.29 |
Acutaas Chemicals Ltd.
₹ 3390.00
-1.99%
Gland Pharma Ltd.
₹ 2475.00
+0.22%
Laurus Labs Ltd.
₹ 1535.50
+1.86%
Alkem Laboratories Ltd.
₹ 5676.00
+0.49%
Biocon Ltd.
₹ 418.25
+3.64%
Divi's Laboratories Ltd.
₹ 6830.50
+0.26%
Granules India Ltd.
₹ 887.00
+0.56%
Ajanta Pharma Ltd.
₹ 3366.00
+1.77%
Zydus Lifesciences Ltd.
₹ 1152.10
-0.60%
Glenmark Pharmaceuticals Ltd.
₹ 2284.50
+0.76%
Wockhardt Ltd.
₹ 1812.80
-1.01%
Aurobindo Pharma Ltd.
₹ 1568.90
-1.17%
Sun Pharmaceutical Industries Ltd.
₹ 1932.90
-0.30%
Neuland Laboratories Ltd.
₹ 19478.00
-0.33%
Ipca Laboratories Ltd.
₹ 1780.10
+0.55%
J B Chemicals & Pharmaceuticals Ltd.
₹ 2420.00
-1.00%
AstraZeneca Pharma India Ltd.
₹ 8115.00
+0.01%
GlaxoSmithKline Pharmaceuticals Ltd.
₹ 2433.00
-0.30%
Pfizer Ltd.
₹ 4720.00
+2.83%
Abbott India Ltd.
₹ 27340.00
+2.13%
Torrent Pharmaceuticals Ltd.
₹ 4890.00
-0.17%
Lupin Ltd.
₹ 2496.00
-0.29%
Dr. Reddy's Laboratories Ltd.
₹ 1246.90
-1.78%
Cipla Ltd.
₹ 1442.00
+0.05%
By signing up I certify terms, conditions & privacy policy